Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40

DRCR Retina Network

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Psychology